Abacus FCF Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-106,247
Closed -$17.6M 74
2025
Q1
$17.6M Sell
106,247
-3,383
-3% -$529K 2.77% 8
2024
Q4
$15.9M Buy
109,630
+51,484
+89% +$7.98M 2.09% 6
2024
Q3
$9.42M Buy
+58,146
New +$9.26M 2.19% 4
2023
Q4
Sell
-1,421
Closed -$221K 169
2023
Q3
$221K Sell
1,421
-4,642
-77% -$766K 0.12% 134
2023
Q2
$1M Sell
6,063
-39
-0.6% -$6.29K 0.51% 75
2023
Q1
$946K Sell
6,102
-8,742
-59% -$1.41M 0.51% 81
2022
Q4
$2.62M Sell
14,844
-333
-2% -$57.5K 1.71% 5
2022
Q3
$2.48M Sell
15,177
-1,110
-7% -$188K 1.71% 4
2022
Q2
$2.89M Sell
16,287
-7,726
-32% -$1.38M 1.77% 4
2022
Q1
$4.26M Buy
24,013
+7,500
+45% +$1.28M 1.42% 8
2021
Q4
$2.82M Hold
16,513
1.39% 10
2021
Q3
$2.71M Buy
16,513
+5,739
+53% +$979K 1.32% 7
2021
Q2
$1.77M Buy
+10,774
New +$1.78M 0.9% 30
2019
Q3
Sell
-7,823
Closed -$1.09M 102
2019
Q2
$1.09M Sell
7,823
-885
-10% -$123K 0.89% 84
2019
Q1
$1.22M Buy
8,708
+413
+5% +$55.3K 0.94% 71
2018
Q4
$1.07M Buy
+8,295
New +$1.16M 0.98% 68
2015
Q1
Sell
-15,716
Closed -$1.64M 118
2014
Q4
$1.64M Buy
+15,716
New +$1.66M 1.01% 83

Other funds holding JNJ

Abacus FCF Advisors's JNJ Position: Q2 2025 in Review

Abacus FCF Advisors sold out of Johnson & Johnson (JNJ) in Q2 2025, closing a stake of 106,247 shares — an estimated $17.6M sold.

Abacus FCF Advisors first reported a position in JNJ in Q4 2014 and held it in 17 quarters. The position peaked at $17.6M in Q1 2025. 4,082 funds tracked by Wall St. Rank hold JNJ as of Q2 2025.

  • Abacus FCF Advisors reported no remaining Johnson & Johnson position as of Q2 2025 after selling out during the quarter.
  • Abacus FCF Advisors sold 106,247 Johnson & Johnson shares in Q2 2025, an estimated $17.6M.
  • Abacus FCF Advisors first reported a position in Johnson & Johnson in Q4 2014 and held it in 17 quarters.
  • Abacus FCF Advisors's Johnson & Johnson position peaked at $17.6M in Q1 2025.
  • 4,082 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2025.

Based on Abacus FCF Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.